LGVN - Longeveron expands enrollment criteria in early-stage ARDS trial

Longeveron (LGVN) announces that the enrollment criteria for its Phase 1 Acute Respiratory Distress Syndrome ((ARDS)) RECOVER trial has been expanded to include mild ARDS, in addition to moderate and severe ARDS caused by COVID-19 or Influenza Infection.The protocol amendment allows for the inclusion of milder cases of ARDS patients who present with the need for supplemental oxygen via high flow nasal cannula, partial or nonrebreathing mask, or non-invasive positive pressure mask.The RECOVER Trial is a double-blind, randomized, placebo-controlled study designed to evaluate the safety and efficacy of up to 3 intravenous administrations of either Lomecel-B or placebo in COVID-19 or Influenza-infected ARDS patients.The primary measures of efficacy are functional lung recovery, recovery from infection, inflammatory status, immune status, and lung imaging.Shares down nearly 5% premarket.

For further details see:

Longeveron expands enrollment criteria in early-stage ARDS trial